Please login to the form below

Not currently logged in
Email:
Password:

Label change for Lilly's Livalo

The US Food and Drug Administration has said Eli Lilly & Company can update the label of cholesterol drug Livalo to remove a warning against the use of the drug together with HIV treatment lopinavir/ritonavir

The US Food and Drug Administration (FDA) has said Eli Lilly & Company can update the label of cholesterol drug Livalo (pitavastatin) to remove a warning against the use of the drug together with HIV treatment lopinavir/ritonavir.

The decision follows a study investigating the effects on patients when co-administered both treatments.

Data from the study demonstrated that there was no significant impact on the blood levels of participants, with minimal interaction between the two drugs.

"Livalo showed minimal drug-drug interactions with a common antiretroviral therapy HIV patients need to fight the disease," said Dr Judith Aberg, director of Virology, Bellevue Hospital Center and director, Division of Infectious Diseases and Immunology, NYU School of Medicine. "For a patient population that is taking multiple medications, this is exciting news."

Drugs to lower cholesterol, such as Livalo, are often prescribed to patients with HIV, with elevated cholesterol a complication associated with both the virus itself and antiretroviral therapies.

18th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...

Infographics